- Home
- LCTX vs EVE Comparison
LCTX vs EVE Comparison
Compare LCTX & EVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- EVE
- Stock Information
- Founded
- LCTX 1990
- EVE 2021
- Country
- LCTX United States
- EVE United States
- Employees
- LCTX N/A
- EVE N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- EVE Blank Checks
- Sector
- LCTX Health Care
- EVE Finance
- Exchange
- LCTX Nasdaq
- EVE Nasdaq
- Market Cap
- LCTX 165.6M
- EVE 159.3M
- IPO Year
- LCTX N/A
- EVE 2021
- Fundamental
- Price
- LCTX $0.90
- EVE $11.00
- Analyst Decision
- LCTX Strong Buy
- EVE
- Analyst Count
- LCTX 3
- EVE 0
- Target Price
- LCTX $5.67
- EVE N/A
- AVG Volume (30 Days)
- LCTX 307.7K
- EVE 12.0K
- Earning Date
- LCTX 11-07-2024
- EVE 01-01-0001
- Dividend Yield
- LCTX N/A
- EVE N/A
- EPS Growth
- LCTX N/A
- EVE 4067.26
- EPS
- LCTX N/A
- EVE 0.24
- Revenue
- LCTX $6,186,000.00
- EVE N/A
- Revenue This Year
- LCTX N/A
- EVE N/A
- Revenue Next Year
- LCTX $119.00
- EVE N/A
- P/E Ratio
- LCTX N/A
- EVE $45.05
- Revenue Growth
- LCTX N/A
- EVE N/A
- 52 Week Low
- LCTX $0.77
- EVE $10.63
- 52 Week High
- LCTX $1.61
- EVE $12.03
- Technical
- Relative Strength Index (RSI)
- LCTX 53.88
- EVE 42.94
- Support Level
- LCTX $0.83
- EVE $10.97
- Resistance Level
- LCTX $0.94
- EVE $11.07
- Average True Range (ATR)
- LCTX 0.05
- EVE 0.06
- MACD
- LCTX 0.01
- EVE -0.00
- Stochastic Oscillator
- LCTX 89.45
- EVE 73.47
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About EVE EVe Mobility Acquisition Corp
EVe Mobility Acquisition Corp is a blank check company.